Nitinotes Secures $10.1M Funding in Series B Round for Revolutionizing Endoscopic Gastroplasty

Nitinotes, a pioneering medical device company based in Caesarea, Israel, has announced a successful funding round, raising an impressive $10.1 million to advance its innovative healthcare solutions. Nitinotes is at the forefront of transforming endoscopic gastroplasty procedures with its flagship product, the EndoZip™. This cutting-edge endoscopic robotic suturing system has garnered significant attention and clinical success, endorsed by prominent Key Opinion Leaders (KOLs) in the field. The funding will be instrumental in accelerating the commercialization efforts of EndoZip™, enabling Nitinotes to bring this safer and simpler suturing solution to a broader range of clinical settings. By streamlining and expediting the suturing process, the EndoZip™ system offers an effective, minimally-invasive alternative for the over 700 million patients suffering from obesity class I & II, for whom traditional bariatric surgery may not be a viable option. This investment showcases the confidence investors have in Nitinotes' mission to improve surgical outcomes and expand access to innovative medical technologies. As Nitinotes prepares to launch EndoZip™ globally, the company is poised to make a significant impact on the treatment landscape for obesity, ultimately contributing to enhanced patient care and health outcomes while paving the way for new standards in endoscopic surgical procedures. This funding marks an exciting milestone for Nitinotes as it moves closer to its goal of revolutionizing the bariatric surgery field and improving the lives of millions affected by obesity.